Multicentric Phase II Trial of Salvage Radiotherapy Combined With Hormonotherapy in Oligometastatic Pelvic Node Relapses of Prostate Cancer

Trial Profile

Multicentric Phase II Trial of Salvage Radiotherapy Combined With Hormonotherapy in Oligometastatic Pelvic Node Relapses of Prostate Cancer

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 10 Sep 2016

At a glance

  • Drugs Leuprorelin (Primary)
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Acronyms GETUG P07; OLIGOPELVIS
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 30 Aug 2016 Planned End Date changed from 1 Sep 2026 to 1 Jul 2026.
    • 30 Aug 2016 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top